Compounds useful in the synthesis of halichondrin b analogs

US2016376294A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016376294-A1
Application numberUS-201615196600-A
CountryUS
Kind codeA1
Filing dateJun 29, 2016
Priority dateJan 26, 2010
Publication dateDec 29, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate. Exemplary compounds are of formula (I), (II), or (III):

First claim

Opening claim text (preview).

What is claimed is: 1 . (canceled) 2 . A compound having the formula: wherein Q is —C(O)H, —CH═CHC(O)OY 1 , —C(R)H(CH2) n OY 1 , or —C(R)HCH 2 C(O)OY 1 ; R is H or —OY 2 ; n is 1 or 2; Y 1 , Y 2 , Y 3 , and Y 4 are each independently H or a hydroxyl protecting group; U is —OY 6 ; Y 5 is H or a hydroxyl protecting group or Y 5 , together with the oxygen atom to which it is bound, is a leaving group; and Y 6 is H or a hydroxyl protecting group or Y 5 , together with the oxygen atom to which it is bound, is a leaving group, provided that when Q is —(CH 2 ) 3 OY 1 , —OY 6 is a leaving group, and Y 1 , Y 3 , and Y 4 are protecting groups, Y 5 is not H, wherein Y 3 and Y 4 are each, independently and together with the oxygen atom to which it is bound, an ester, carbonate, carbamate, sulfonate, or ether hydroxyl protecting group, or Y 3 and Y 4 together with the oxygen atoms to which they are bound are a cyclic carbonate, cyclic boronate or cyclic silylene hydroxyl protecting group, or Y 3 and Y 4 together are acetal, ketal, or 1,1,3,3-tetraisopropylsiloxanediyl. 3 . The compound of claim 2 having the formula (IIIa): 4 . The compound of claim 2 , wherein Q is —(CH 2 ) 3 OY 1 . 5 . The compound of claim 4 , wherein Y 1 , together with the oxygen atom to which it is bound, is an ester, carbonate, carbamate, sulfonate, or ether hydroxyl protecting group; and Y 5 , together with the oxygen atom to which it is bound, is an ester, carbonate, carbamate, sulfonate, or ether hydroxyl protecting group. 6 . The compound of claim 5 , wherein Y 1 is pivaloyl, acetyl, benzoyl, p-bromobenzoyl, p-methoxybenzoyl, 1-naphthoyl, 2-naphthoyl, o-phthaloyl, benzyl, p-methoxybenzyl, triphenylmethyl, tri(C1-C6 alkyl)silyl, tri(C6-C10 aryl or C1-C6 heteroaryl)silyl, di(C6-C10 aryl or C1-C6 heteroaryl)(C1-C6 alkyl)silyl, or (C6-C10 aryl or C1-C6 heteroaryl)di(C1-C6 alkyl)silyl. 7 . The compound of claim 2 , wherein Y 3 and Y 4 are each independently tri(C1-C6 alkyl)silyl, tri(C6-C10 aryl or C1-C6 heteroaryl)silyl, di(C6-C10 aryl or C1-C6 heteroaryl)(C1-C6 alkyl)silyl, or (C6-C10 aryl or C1-C6 heteroaryl)di(C1-C6 alkyl)silyl, or Y 3 and Y 4 are together di(C1-C6)alkylsilylene. 8 . The compound of claim 5 , wherein Y 5 is acetyl, benzoyl, p-bromobenzoyl, p-methoxybenzoyl, 1-naphthoyl, 2-naphthoyl, or o-phthaloyl. 9 . The compound of claim 2 , wherein Y 5 is H or a hydroxyl protecting group. 10 . The compound of claim 2 , wherein Y 6 is H. 11 . The compound of claim 2 , wherein —OY 6 is a leaving group. 12 . The compound of claim 11 , wherein —OY6 is (C1-C6)alkylsulfonate, (C6-C10 aryl or C1-C6 heteroaryl)sulfonate, (C6-C15)aryl(C1-C6)alkylsulfonate, or (C1-C6)heteroaryl(C1-C6)alkylsulfonate. 13 . The compound of claim 12 , wherein —OY 6 is mesylate, toluenesulfonate, isopropylsulfonate, phenylsulfonate, or benzylsulfonate.

Assignees

Inventors

Classifications

  • C07F7/1804Primary

    Compounds having Si-O-C linkages (Si-O-acyl linkages C07F7/1896) · CPC title

  • Radicals substituted by oxygen atoms · CPC title

  • C07D405/06Primary

    linked by a carbon chain containing only aliphatic carbon atoms · CPC title

  • linked by a carbon chain containing only aliphatic carbon atoms · CPC title

  • with substituted hydrocarbon radicals attached to ring carbon atoms · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016376294A1 cover?
In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate. Exemplary compounds are of formula (I), (II), or (III):
Who is the assignee on this patent?
Eisai R&D Man Co Ltd
What technology area does this patent fall under?
Primary CPC classification C07F7/1804. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Dec 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).